NCT05291091Phase 2Completed

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Study sponsor: Edgewise Therapeutics, Inc. · EWTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09-07Actual
Enrollment · participants244Actual
Source updated2026-09-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of adverse events in those treated with sevasemten or placebo Measure: Severity of adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in the North Star Ambulatory Assessment scale. After: Measure: Number of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Severity of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in total North Star Ambulatory Assessment score.

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2026. After: 7 Sep 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Actual enrollment increased by 69 participants

Before: 175 participants (actual). After: 244 participants (actual).

Check registry source

· 1 field changed

Primary completion date changed

Before: Aug 2026. After: Sep 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview